Establishment and characterization of cell lines from a novel mouse model of poorly differentiated thyroid carcinoma: Powerful tools for basic and preclinical research

Thyroid

Volumn 21, Issue 9, 2011, Pages 1001-1007

  Dima, Mariavittoria ^a   Miller, Kelly A ^b   Antico Arciuch, Valeria Gabriela ^a   Di Cristofano, Antonio ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; EVEROLIMUS; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SODIUM IODIDE SYMPORTER;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CLINICAL RESEARCH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; IMMUNOCOMPETENCE; LUNG METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; THYROID NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052431779     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0030     Document Type: Article

References (12)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
2. Wein RO, Weber RS 2011 Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg DOI: 10.1002/mc.20668.
3. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, Papotti M, Bussolati G, Lloyd RV 2010 Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol 23:1269-1278.
4. Patel KN, Shaha AR 2006 Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13:119-128.
5. Shan YS, Fang JH, Lai MD, Yen MC, Lin PW, Hsu HP, Lin CY, Chen YL 2010 Establishment of an orthotopic transplantable gastric cancer animal model for studying the immunological effects of new cancer therapeutic modules. Mol Carcinog DOI: 10.1097/moo.0b013e3283432f3d.
6. Quinn BA, Xiao F, Bickel L, Martin L, Hua X, Klein-Szanto A, Connolly DC 2010 Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res 3:24-40.
7. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A 2009 Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 69:3689-3694.
8. Jeker LT, Hejazi M, Burek CL, Rose NR, Caturegli P 1999 Mouse thyroid primary culture. Biochem Biophys Res Commun 257:511-515. (Pubitemid 29301473)
9. Dang CV, Semenza GL 1999 Oncogenic alterations of metabolism. Trends Biochem Sci 24:68-72. (Pubitemid 29346576)
10. Wallace DC 2005 Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 70:363-374. (Pubitemid 44124891)
11. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL 2004 Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324:269-275. (Pubitemid 39311489)
12. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106-3116.